Evidence map›Paper›PMID 41514089›Full record

ArticleMycopathologia2026

Candidozyma auris in The Netherlands: No Evidence of Nosocomial Transmission Supported by Effective Infection Control Policies.

Chiara C de Groot, Bram Spruijtenburg, Juliëtte A Severin, Karin van Dijk, Jochem B Buil, Paul E Verweij, Auke W de Jong, Eelco F J Meijer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mycopathologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chiara C de GrootCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.ORCID http://orcid.org/0009-0005-1721-8596
Bram SpruijtenburgRadboudumc-CWZ Center of Expertise for Mycology, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-6734-361X
Juliëtte A SeverinDepartment of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-5222-3017
Karin van DijkDepartment of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Jochem B BuilDepartment of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-4031-0778
Paul E VerweijCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.ORCID http://orcid.org/0000-0002-8600-9860
Auke W de JongCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.ORCID http://orcid.org/0000-0002-0914-4612
Eelco F J MeijerRadboudumc-CWZ Center of Expertise for Mycology, Nijmegen, The Netherlands. Eelco.Meijer@cwz.nl.ORCID http://orcid.org/0000-0002-0226-024X

Funding

ZonMw 10150022310025
6 · The paper itself

Abstract

The yeast Candidozyma auris has emerged globally as a major threat to public health. Outbreaks are frequently reported and difficult to control. In the Netherlands, C. auris is rarely detected although national surveillance has been set up. Here, we present all Dutch C. auris cases reported from March 2018 until April 2025. Antifungal susceptibility testing (AFST) using broth microdilution and whole genome sequencing (WGS) were conducted to evaluate antifungal resistance and genetic relatedness. A total of 26 cases of C. auris infection or colonization were reported across 22 different medical institutions in the Netherlands. Most patients had a history of travel to countries with prior reports of C. auris and were hospitalized in foreign medical centers. All patients were admitted in isolation, and all but one remained in isolation for the duration of their hospitalization. WGS showed isolates belonged to clade I or III. Analysis of travel history, contact tracing and WGS data showed no evidence of nosocomial transmission. All isolates were non-wild type to fluconazole with many harboring corresponding mutations in ERG11. One isolate was non-wild type to 5FC and another one to echinocandins including rezafungin. The latter harbored a FKS1

Indexed as

Cross InfectionInfection ControlSaccharomycetalesAntifungal AgentsCandida aurisDrug Resistance, FungalHumansMicrobial Sensitivity TestsNetherlandsWhole Genome SequencingAntifungal AgentsAntifungal resistanceCandidozyma aurisInfection preventionOutbreakSurveillanceWhole genome sequencing

Identifiers

PMID41514089
PMCPMC12789240

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.